Supplemental Tables 1-3 from A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Tables 1-3. Supplementary Table 1: Correlations in the vandetanib/RT/TMZ arm between best radiographic responses with pre-treatment and on-treatment changes in blood biomarkers. Supplementary Table 2: Correlations in the vandetanib/RT/TMZ arm between overall survival with pre-treatment and on-treatment changes in blood biomarkers. Supplementary Table 3: Comparison of PFS or OS by log-rank p-value based on tissue biomarker analysis
Authors: Eudocia Q. Lee, Thomas J. Kaley, Dan G. Duda, David Schiff, Andrew B. Lassman, Eric T. Wong, Tom Mikkelsen, Benjamin W. Purow, Alona Muzikansky, Marek Ancukiewicz, Jason T. Huse, Shakti Ramkissoon, Jan Drappatz, Andrew D. Norden, Rameen Beroukhim, Stephanie E. Weiss, Brian M. Alexander, Christine S. McCluskey, Mary Gerard, Katrina H. Smith, Rakesh K. Jain, Tracy T. Batchelor, Keith L. Ligon, Patrick Y. Wen
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362395876